...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: Epigenetic Modifiers as Potential Therapeutic Targets in Diabetic Kidney Disease

Specifically, the article states under Section 6:

"Although there was a predefined secondary endpoint of change in kidney function in patients with eGFR <60 mL/min/1.73 m2, formal statistical testing of the key secondary end points and prespecified subgroups was not performed as this was precluded by the prespecified analysis plan once the primary endpoint was not met."

Could this explain why we have not seen the missing kidney data?

Share
New Message
Please login to post a reply